Afucosylated mAb expression benefits therapeutic antibody efficacy


Currently, at least 35 glycoengineered antibodies, with their Fc fucose partially or entirely removed, have been investigated in animal models or clinical trials. The absence of fucose on the Fc N-glycan increases IgG1 Fc binding affinity to the FcγRIIIa on immune effector cells like natural killer cells. It results in increased antibody-dependent cellular cytotoxicity (ADCC). […]

Suggested Reading